Skip Navigation

Annals of Oncology 2007 18(Supplement 10):x11-x19; doi:10.1093/annonc/mdm409
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DePrimo, S.
Right arrow Articles by Bello, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DePrimo, S.
Right arrow Articles by Bello, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

symposium articles

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

SE DePrimo1,* and C Bello2

1 Department of Translational Medicine, Pfizer Global Research and Development
2 Department of Clinical Pharmacology, Pfizer Global Research and Development, La Jolla, CA, USA

* Correspondence to: Dr Samuel DePrimo, Pfizer La Jolla Laboratories, 10646 Science Center Drive, San Diego, CA 92121, USA. Tel: +1-619-622-7369; Fax: +1-858-678-8272; E-mail: sam.deprimo{at}pfizer.com

Conventional methods to assess the clinical activity of new agents that target specific biological pathways involved in tumour pathology may not provide correlation with clinically relevant outcomes such as patient survival or progression-free disease, and new and alternative methods should be explored. Biomarkers can assist in evaluation, and once validated, serve as a surrogate for clinical activity. Angiogenesis, a process well known to be involved in tumour growth and metastasis, is the target of several agents available today in the treatment of cancer. Laboratory assays used to detect proteins involved in angiogenesis and emerging imaging approaches have provided the bulk of the biomarker data to date in this area, and have already corroborated aspects of the biochemical basis of anti-angiogenic strategy. This symposium article will provide a brief overview of biomarker data in several different tumour types and discuss the effect that sunitinib and other anti-angiogenic agents have on these biomarkers. Surrogate biomarkers discussed include soluble proteins found in the blood or urine, circulating endothelial cells and their progenitors, and non-invasive imaging techniques.

Key words: biomarkers, anti-angiogenesis, surrogate, sunitinib, VEGF


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.